Skip to content
Evigrade
CriticalCentrally acting psychostimulant×Antidepressant, irreversible non-selective monoamine oxidase inhibitor (MAO-A and MAO-B), amphetamine derivative

Updated · Methodology

Mechanism

Methylphenidate is a mild central nervous system stimulant from the group of centrally acting sympathomimetics. It is thought to block the neuronal reuptake of noradrenaline and dopamine and to increase their release (methylphenidate summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, section 5.1). Tranylcypromine irreversibly and non-selectively inhibits monoamine oxidase (MAO) types A and B, the enzyme that breaks down serotonin, noradrenaline and dopamine inside neurons, so the central nervous system has more of these transmitters (tranylcypromine SmPC, AEMPS, section 5.1). According to the Spanish methylphenidate SmPC, combining methylphenidate with irreversible non-selective MAO inhibitors carries a risk of hypertensive crisis (methylphenidate SmPC, AEMPS, sections 4.3 and 4.5). According to the US label, combining central nervous system stimulants with MAO inhibitors can cause hypertensive crisis (methylphenidate label, US Food and Drug Administration, FDA, section 7). Cytochrome P450 (CYP) enzymes do not metabolise methylphenidate to a clinically relevant extent (methylphenidate SmPC, AEMPS, section 4.5).

Symptoms

The main risk of the combination is hypertensive crisis (methylphenidate summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5; tranylcypromine label, US Food and Drug Administration, FDA, section 7.1). According to the US methylphenidate label, possible outcomes include death, stroke, myocardial infarction, aortic dissection, eye complications, eclampsia, pulmonary oedema and renal failure (FDA methylphenidate label, section 7). During tranylcypromine treatment, a hypertensive crisis may come with a fast heart rate, facial flushing, headache (especially at the back of the head), neck stiffness, nausea, vomiting and sensitivity to light. In isolated cases, particularly with a drug interaction, it can lead to intracranial haemorrhage (tranylcypromine SmPC, AEMPS, section 4.8). The US tranylcypromine label describes a hypertensive emergency as severely raised blood pressure (for example, above 180/120 mm Hg) with signs of organ damage. It may come with sweating, dilated pupils, shortness of breath, confusion, constricting chest pain and seizures (tranylcypromine FDA label, section 5.2).

Management

The combination is contraindicated. The Spanish methylphenidate summaries of product characteristics (SmPCs) do not allow methylphenidate during treatment with irreversible non-selective monoamine oxidase (MAO) inhibitors or for at least 14 days after stopping them, because of the risk of hypertensive crisis (methylphenidate SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS, sections 4.3 and 4.5). According to its own SmPC, tranylcypromine is exactly such an inhibitor (tranylcypromine SmPC, AEMPS, section 5.1). The US labels contraindicate the combination on both sides. The tranylcypromine label lists methylphenidates and their derivatives among the contraindicated products (tranylcypromine label, US Food and Drug Administration, FDA, sections 4.1 and 7.1), and the methylphenidate label contraindicates its use with MAO inhibitors or within 14 days of stopping them (FDA methylphenidate label, sections 4 and 7). Start methylphenidate no earlier than 14 days after stopping tranylcypromine (methylphenidate SmPC, AEMPS, section 4.3; FDA methylphenidate label, section 4; tranylcypromine SmPC, AEMPS, section 4.2). Start tranylcypromine after a contraindicated drug no earlier than 4–5 half-lives of that drug or any active metabolite (tranylcypromine FDA label, section 7.1). Before prescribing methylphenidate, assess cardiovascular status, including blood pressure and heart rhythm (methylphenidate SmPC, AEMPS, section 4.2), and measure blood pressure before starting tranylcypromine (tranylcypromine FDA label, section 2.4). During methylphenidate treatment, monitor for hypertension and tachycardia (FDA methylphenidate label, section 5.3). With tranylcypromine, monitor blood pressure closely (tranylcypromine FDA label, section 5.2). At the first signs of a hypertensive crisis, such as palpitations or headache, interrupt treatment, assess the patient at once and stop any drug that may have caused it. If blood pressure is severely raised (for example, above 180/120 mm Hg) with signs of organ damage, lower it immediately (tranylcypromine FDA label, section 5.2).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Methylphenidate

Other interactions with Tranylcypromine